Diatron Celebrates Latest FDA Approval

Abacus 3CP hematology analyzers prepared for US market introduction

 

BUDAPEST, HUNGARY (October 15, 2012): Diatron Group (Diatron), global provider of hematology and clinical chemistry analyzers, has recently gained the US Food and Drug Administration (FDA) 510(k) pre-market approval for its Abacus 3CP, fully automated, bench-top hematology analyzer. The news follows the FDA approval in April of the Abacus 5, the most advanced model of Diatron’s range of hematology analyzers.

 

The Abacus 3CP analyzer is one of a range of three, 3-part differential analyzers from Diatron, which also includes the Abacus Junior 30 and Abacus 380. Together these offer from 12 to 20 parameters, with throughputs of between 30 to 80 samples per hour, to provide flexible, cost-effective solutions for low to medium-sized customers. The Abacus 3CP, which can process up to 60 samples per hour, has an internal memory capable of storing 10,000 records with full histograms, and individual patient data.

The Abacus 5 model is designed to guarantee precise and accurate 5-part differential results generating maximum value at low running costs. It offers a patented laser-based optical system that ensures precise and accurate 5-part differential results, Capable of processing 60 samples per hour, the Abacus 5 can store more than 100,000 results in its large database. Both Abacus ranges possess easy-to-use, color touch screens with multilingual operating systems and their compact size makes them ideal for physician’s offices or laboratories with minimal available desk-top space.

 

Commenting on the news, Jim Schepp, CEO at Diatron said: “We are delighted with this latest FDA approval of our Abacus 3CP hematology analyzer. It is a step forward for patient care in the US, as it allows hospital and physician office laboratories to access these instruments and benefit from this accurate and cost-effective technology”.

 

Diatron’s Abacus family of compact hematology analyzers provide high quality and fast complete blood count results making them suitable for laboratories, hospital clinics and physician offices. Highly regarded for its excellence in the manufacture of hematology analyzers, Diatron has sold more than 30,000 units in over 100 international markets through Diatron MI Plc. This subsidiary of the Diatron Group is based in Budapest, Hungary and has more than 20 years’ experience in the hematology market.

 

For more information please visit the Diatron Group website: http://www.diatron.com

 

The Diatron Group

Diatron’s vision since the company’s foundation in 1989, is to become a worldwide leader in-vitro diagnostics, providing customers with a broad portfolio of high-quality tailored solutions. In its new production facility in Budapest, Hungary, the extensive R&D/Engineering team develops and manufactures compact hematology and clinical chemistry analyzers and reagents for the human medical and veterinary markets.

 

Diatron is a portfolio company of The Riverside Company, a global private equity firm focused on acquiring growing businesses valued at up to $200 million (€200 million in Europe). Founded in 1988, Riverside’s international portfolio now includes 80 companies, and it has more than $3 billion/€2.5 billion in assets under management.

See www.riversidecompany.com for more information.